NGS Serves to Promote ‎Personalized Medicine: A Case-‎Report of a Patient with Invasive ‎Breast Carcinoma

Mirsadeghi, Leila; Haji Hosseini, Reza; Banaei, Ali Mohammad; Kavousi, Kaveh

doi:10.30473/eab.2021.58111.1823

Document Type : Case report

Authors

¹ Ph. D., Department of Biology, Payame ‎Noor University, Tehran, Iran

² Professor, Department of Biology, Payame ‎Noor University, Tehran, Iran

³ Assistant Professor, Laboratory of Genomics and Epigenomics ‎‎(LGE), Department of Biochemistry, Institute of Biochemistry ‎and Biophysics (IBB), University of Tehran, Tehran, Iran

⁴ Assistant Professor, Laboratory of Complex Biological Systems ‎and Bioinformatics (CBB), Department of Bioinformatics, ‎Institute of Biochemistry and Biophysics (IBB), University of ‎Tehran, Tehran, Iran

https://doi.org/10.30473/eab.2021.58111.1823

Abstract

The emergence of personalized medicine based on molecular techniques, such as next-generation sequencing, has increased our understanding of drivers of complex diseases, including cancers. In many cases due to the complexity of cancer, it is difficult for human physicians and biologists to make decisions on the basis solely of clinical practice or laboratory evidence. Thus, the personalized medicine approach comes into play and provides large volumes and valuable data for experts. Further, data analysis with bioinformatic tools has opened a new horizon in the process of prognosis and screening of in risk individuals. It has caused significant recent advances in diagnostic technology and improved targeted treatments. In the present study, archived formalin-fixed paraffin-embedded tissue from an Iranian female patient with invasive breast carcinoma was investigated. In this way, after DNA extraction and purification, the whole exome was sequenced and the mutation data were analyzed. Obtained information could help to the enrichment of the Iranian genome databases. In the light of this research and by studying other Iranian samples, we can provide an optimized roadmap for precision oncologists to increase the life expectancy of breast cancer patients.

Keywords

20.1001.1.23222387.1400.10.3.5.9

References

Aureli, A.; Canossi, A.; Del Beato, T.; Buonomo, O.; Rossi, P.; Roselli, M.; … Sconocchia, G. (2020). Breast Cancer Is Associated with Increased HLA-DRB1* 11: 01 and HLA-DRB1* 10: 01 Allele Frequency in a Population of Patients from Central Italy. Immunological Investigations; 49(5), 489-497.

Chai, X.; Domchek, S.; Kauff, N.; Rebbeck, T.; Chen, J. (2015). RE: Breast Cancer Risk After Salpingo-Oophorectomy in Healthy BRCA1/2 Mutation Carriers: Revisiting the Evidence for Risk Reduction. Journal of the National Cancer Institute; 107(9), djv217.

Consortium, G.O. (2004). The Gene Ontology (GO) database and informatics resource. Nucleic Acids Research; 32(suppl_1), D258-D261.

Ebrahimi, M.; Vahdaninia, M.; Montazeri, A. (2015). Risk factors for breast cancer in Iran: a case-control study. Breast Cancer Research; 4: 4.

Fabregat, A.; Jupe, S.; Matthews, L.; Sidiropoulos, K.; Gillespie, M.; Garapati, P.; … May, B. (2017). The reactome pathway knowledgebase. Nucleic Acids Research; 46(D1): D649-D655.

Gambardella, V.; Tarazona, N.; Cejalvo, J.M.; Lombardi, P.; Huerta, M.; Roselló, S.; … Cervantes, A. (2020). Personalized medicine: recent progress in cancer therapy. Cancers; 12(4): 1009.

Gourraud, P.-A.; Khankhanian, P.; Cereb, N.; Yang, S.Y.; Feolo, M.; Maiers, M.; … Oksenberg, J. (2014). HLA diversity in the 1000 genomes dataset. PloS One; 9(7): e97282.

Greenman, C.; Stephens, P.; Smith, R.; Dalgliesh, G.L.; Hunter, C.; Bignell, G.; … Stevens, C. (2007). Patterns of somatic mutation in human cancer genomes. Nature; 446(7132): 153-158.

Griffith, O.L.; Gray, J.W. (2011). ’Omic approaches to preventing or managing metastatic breast cancer. Breast Cancer Research; 13(6): 230.

Jiang, Y.; Jiang, Y.; Wang, S.; Zhang, Q.; Ding, X. (2019). Optimal sequencing depth design for whole genome re-sequencing in pigs. BMC Bioinformatics; 20(1): 1-12.

Kanehisa, M.; Goto, S. (2000). KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Research; 28(1): 27-30.

Kumar, A.; Singla, A. (2019). Epidemiology of Breast Cancer: Current Figures and Trends. In Preventive Oncology for the Gynecologist (pp. 335–339). Springer.

Liu, Y.; Tian, F.; Hu, Z.; DeLisi, C. (2015). Evaluation and integration of cancer gene classifiers: identification and ranking of plausible drivers. Scientific Reports, 5.

McKenzie, A.J.H.; Dilks, H.; Jones, S.F.; Burris III, H. (2019). Should next-generation sequencing tests be performed on all cancer patients? Expert Review of Molecular Diagnostics; 19(2): 89-93.

Mirsadeghi, L.; Hosseini, R.H.; Banaei-Moghaddam, A.M.; Kavousi, K. (2021). EARN: an ensemble machine learning algorithm to predict driver genes in metastatic breast cancer. BMC Medical Genomics; 14(1), 1-19.

Morganti, S.; Tarantino, P.; Ferraro, E.; D’Amico, P.; Duso, B.A.; Curigliano, G. (2019). cancer. Translational Research and Onco-Omics Applications in the Era of Cancer Personal Genomics; 9-30.

Nishimura, D. (2001). BioCarta. Biotech Software & Internet Report: The Computer Software Journal for Scient; 2(3): 117-120.

Schaefer, C.F.; Anthony, K.; Krupa, S.; Buchoff, J.; Day, M.; Hannay, T.; Buetow, K.H. (2009). PID: the pathway interaction database. Nucleic Acids Research; 37(suppl_1), D674-D679.

Sheikine, Y.; Kuo, F.C.; Lindeman, N.I. (2017). Clinical and technical aspects of genomic diagnostics for precision oncology. Journal of Clinical Oncology; 35(9): 929-933.

Smith, N.G.; Gyanchandani, R.; Shah, O.S.; Gurda, G.T.; Lucas, P.C.; Hartmaier, R.J.; … Kota, K. (2019). Targeted mutation detection in breast cancer using MammaSeq^TM. Breast Cancer Research; 21(1): 22.

Truty, R.; Paul, J.; Kennemer, M.; Lincoln, S.E.; Olivares, E.; Nussbaum, R.L.; Aradhya, S. (2019). Prevalence and properties of intragenic copy-number variation in Mendelian disease genes. Genetics in Medicine; 21(1): 114-123.

Tung, N.; Battelli, C.; Allen, B.; Kaldate, R.; Bhatnagar, S.; Bowles, K.; … Ellisen, L. (2015). Frequency of mutations in individuals with breast cancer referred for BRCA 1 and BRCA 2 testing using next‐generation sequencing with a 25‐gene panel. Cancer; 121(1): 25-33.

Wang, K.; Li, M.; Hakonarson, H. (2010). ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Research; 38(16): e164-e164.

Watson, I.R.; Takahashi, K.; Futreal, P.A.; Chin, L. (2013). Emerging patterns of somatic mutations in cancer. Nature Reviews Genetics; 14(10): 703-718.

Wood, L.D.; Parsons, D.W.; Jones, S.; Lin, J.; Sjöblom, T.; Leary, R.J.; … Ptak, J. (2007). The genomic landscapes of human breast and colorectal cancers. Science; 318(5853): 1108-1113.

Experimental animal Biology

NGS Serves to Promote ‎Personalized Medicine: A Case-‎Report of a Patient with Invasive ‎Breast Carcinoma

References

References

Volume 10, Issue 3 - Serial Number 39
February 2022
Pages 55-66

NGS Serves to Promote ‎Personalized Medicine: A Case-‎Report of a Patient with Invasive ‎Breast Carcinoma

References

References

Volume 10, Issue 3 - Serial Number 39February 2022Pages 55-66

Volume 10, Issue 3 - Serial Number 39
February 2022
Pages 55-66